Hofseth BioCare
Manufacturing · Norway · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Alesund, More og Romsdal, NorwayPhone Number
+47 40246260Website
www.hofsethbiocare.noRevenue
$12.9 MillionIndustry
About Hofseth BioCare
Is Hofseth BioCare your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Hofseth BioCare has recently received funding, and reach out quickly before it becomes old news!
Hofseth BioCare, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Hofseth BioCare had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Hofseth BioCare
Check out if Hofseth BioCare is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Hofseth BioCare launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Hofseth BioCare recently announced quarterly report
Funding: Get notified immidiatlly once Hofseth BioCare has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Hofseth BioCare is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hofseth BioCare is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hofseth BioCare.
Hofseth BioCare Tech Stack
A closer look at the technologies used by Hofseth BioCare
Most Recent Scoops
Hofseth BioCare News & Media
Hofseth BioCare ASA: SECOND QUARTER 2026 FINANCIAL REPORT
HBC recorded total operating revenues of NOK 65.7 million in the second quarter of 2026, compared to NOK 68.4 million in the same period last year. Net operating revenues were NOK 63.1 million, down from NOK 67.8 million in Q2 2025. EBITDA for the quarter was negative NOK 2.7 million, compared to negative NOK 5.4 million in Q2 2025. The Operational EBITDA* amounted to negative NOK 0.6 million (positive NOK 1.3 million in Q2 2025), excludingHOFSETH BIOCARE ASA: EXTRAORDINARY GENERAL MEETING COMPLETED
Hofseth BioCare ASA held an Extraordinary General Meeting on 30 July 2026. All proposals were resolved as presented in the notice issued on 9 July 2026.Hofseth BioCare ASA: NEW PEER-REVIEWED CLINICAL STUDY ON PROGO® PUBLISHED IN BIOMEDICINES DEMONSTRATES GLP-1 BENEFITS AND AN INCREASE LEAN MUSCLE MASS
Hofseth BioCare ASA (“HBC”) announces the publication of a new peer-reviewed clinical study on its salmon protein hydrolysate ProGo® in the international scientific journal Biomedicines. The randomised, double-blind, active-controlled pilot study reports that 56 days of daily ProGo® supplementation improved multiple biological markers relevant to healthy ageing and metabolic health in overweight adults, while a protein-matched whey comparator did not.HOFSETH BIOCARE ASA: CONTEMPLATED PRIVATE PLACEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hofseth BioCare
Hofseth BioCare is a fully integrated salmon business focused on enhancing human nutrition and wellbeing through sustainable practices. They offer premium bioactive marine ingredients derived from Norwegian salmon off-cuts, ensuring high nutritional value without additives or waste. The company is a leader in marine lipid and peptide research, util... Read More